October 10, 2025 — Leads & Copy — Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) announced new data demonstrating tolerability and initial efficacy of SAT-3247 in adults (aged 20-27 years) with Duchenne muscular dystrophy (Duchenne or DMD) at the 30th Annual Congress of the World Muscle Society in Vienna, Austria.
Frank Gleeson, co-founder and CEO of Satellos, stated the clinical results from the 28-day clinical study in adults with Duchenne provide an important validation of SAT-3247’s potential to be a safe and clinically meaningful treatment. He added that the company is excited and confident in progressing into its next phase of clinical studies.
Data presented at the meeting demonstrate that SAT-3247 was safe and well-tolerated across the Phase 1a/b study with a desirable pharmacokinetic (PK) profile. The presentation also included new analyses of exploratory measures of early drug effect.
Individuals treated with SAT-3247 over a 28-day period demonstrated an increase in grip strength far greater than seen in the Duchenne natural history in this age group. Furthermore, participants exhibited a 5.8% mean improvement of predicted forced vital capacity; such an increase is also inconsistent with natural history with declines about 5% annually among adults with Duchenne.
Wildon Farwell, M.D., Satellos chief medical officer, said these early signs of efficacy in adults with more advanced disease are incredibly encouraging and support expanding the clinical program to the broader Duchenne community.
The five adult patients, aged 20-27 years, who participated in the Phase 1b trial are now invited to enroll in an 11-month open-label, follow-up study of SAT-3247, which will also enroll additional males with DMD, aged 16-25 years.
Based on the initial safety and efficacy data from the Phase 1a/b trial, Satellos is also planning a Phase 2 randomized, double-blind, placebo-controlled, global, proof-of-concept study of SAT-3247 in ambulatory children with DMD. The company has recently submitted regulatory filings in the U.S. and globally to advance this study.
Full details from the poster presentations will be available on the Events and Presentations page of the Satellos website.
ABOUT SAT-3247
SAT-3247 is a proprietary, oral, small molecule drug being developed by Satellos as a novel treatment to regenerate skeletal muscle that is lost in Duchenne muscular dystrophy and other degenerative or injury conditions.
ABOUT SATELLOS BIOSCIENCE INC.
Satellos is a clinical-stage drug development company focused on restoring natural muscle repair and regeneration in degenerative muscle diseases.
Contact: Wildon Farwell, M.D., Satellos chief medical officer.
Source: Satellos Bioscience Inc.
